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Abstract: The proliferation and migration of endothelial
cells are vascular events of inflammation, a process
which can also potentiate the effects of promigratory
factors. With the aim of investigating possible modifi-
cations in the activity of erythropoietin (Epo) in an in-
flammatory environment, we found that Epo at a non-
promigratory concentration was capable of stimulating
EA.hy926 endothelial cell migration when TNF-α was
present. VCAM-1 and ICAM-1 expression, as well as
adhesion of monocytic THP-1 cells to endothelial layers
were also increased. Structurally modified Epo (carba-
mylation or N-homocysteinylation) did not exhibit these
effects. The sensitizing effect of TNF-α on Epo activity
was mediated by the Epo receptor. Inhibition assays
targeting the PI3K/mTOR/NF-κB pathway, shared by Epo
and TNF-α, show a cross-talk between both cytokines. As
observed in assays using antioxidants, cell migration
elicited by TNF-α + Epo depended on TNF-α-generated
reactive oxygen species (ROS). ROS-mediated inactiva-
tion of protein tyrosine phosphatase 1B (PTP1B),
involved in Epo signaling termination, could explain the
synergistic effect of these cytokines. Our results suggest
that ROS generated by inflammation inactivate PTP1B,
causing the Epo signal to last longer. This mechanism,
along with the cross-talk between both cytokines, could
explain the sensitizing action of TNF-α on the migratory
effect of Epo.
Keywords: cytokine receptors; endothelial cells;
erythropoietin; protein tyrosine phosphatase 1B; reactive
oxygen species; tumor necrosis factor α.
Introduction
Erythropoietin (Epo) is the required cytokine for promoting
survival, proliferation and differentiation of erythroid
progenitor cells through its homodimeric receptor EpoR,
thus maintaining the adequate mass of mature erythroid
cells. However, erythropoiesis stimulation is not the only
function of this hormone. The widespread distribution of
EpoR in brain cells, myoblasts, adipocytes, endothelium
and other cell types permits the activity of Epo in non-
hematopoietic tissues, particularly cell protection against
proapoptotic stimuli.
Expression of EpoR in endothelial cells facilitates
the promotion of angiogenesis by Epo. This process may
contribute to cardioprotection in ischemic injury, a
condition characterized by the release of nuclear factor
κB (NF-κB), reactive oxygen species (ROS) accumulation
and inflammation. In this context, previous studies have
shown that Epo increased endothelial cell proliferation
and neovascularization (Doleschel et al. 2015; Zhu et al.
2019).
Epo binding induces phosphorylation of Janus kinase 2
(Jak2), thus initiating the activation of downstream signaling
pathways such as that of the signal transducer and activator
of transcription 5 (STAT5), the extracellular signal-regulated
kinase (ERK), and the phosphatidylinositol 3-kinase (PI3K)/
AKT. Since the phosphorylation of protein tyrosyl residues is
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a critical event in many signaling pathways involved in
proliferation, differentiation and cellular response to Epo,
phosphatases become important factors in the down-
regulation of such activities. Among these enzymes, the
protein tyrosine phosphatase (PTP) family and its proto-
type PTP1B in particular, have been characterized in the
attenuation of Epo signaling (Callero et al. 2007; Myers
et al. 2001).
It is well-known that the therapeutical action of re-
combinant human erythropoietin (rhuEpo) is widely used
to counteract anemia, especially in patients with chronic
diseases. The fact that these chronic pathologies are
strongly associated with inflammation highlights the
importance of understanding the activity of Epo in the
presence of proinflammatory cytokines. Stemming from
this, the aim of the present investigation was to study
whether any biological function of the hormone Epo may
be modified by an inflammatory environment in endothe-
lial cells. Epo was used at a non-promigratory concentra-
tion in an inflammatory environment generated by the
presence of tumor necrosis factor alpha (TNF-α). This
model was applied in assays to evaluate the effect of the
simultaneous action of both cytokines on endothelial cell
migration, expression of adhesion molecules and cell
adhesion, and to further elucidate the mechanisms
involved.
On the other hand, in candidates to long-term Epo
treatment, such as patients with chronic kidney disease
(CKD) or chronic heart failure (CHF), increased levels of
structurally modified circulating proteins have been re-
ported (Kraus et al. 1998; Sikora et al. 2014), due to their
reaction with accumulated metabolic substances associ-
ated to the pathology. In renal patients, who routinely
receive rhuEpo therapy to overcome anemia, plasma pro-
teins may be carbamylated by the cyanate derived from
urea hydrolysis. It is known that carbamylated Epo (cEpo)
loses its erythropoietic ability but retains its antiapoptotic
capacity (Chamorro et al. 2013; Leist et al. 2004). Hyper-
homocysteinemia, frequently found in CHF, is another
condition that may cause protein modification, in this case
through homocysteinylation. Epo N-homocysteinylation
by reaction with homocysteine thiolactone (HTL), the
highly reactive metabolite of homocysteine, generates
oligomeric structures with loss of erythropoietic activity
(Schiappacasse et al. 2018). In the light of this evidence, it
seemed interesting to study the action of those modified
erythropoietins on endothelial cells under an inflammatory
environment to compare it with that of the native Epo.
The results of this work will increase the knowledge of
Epo behavior on endothelial cells in an inflammatory
environment, a state closely associated to anemia of
chronic diseases, and are expected to be used in the future
to adequate therapeutic protocols.
Results
Effect of TNF-α and erythropoietin on
endothelial cell migration
Evidence exists of a critical role of TNF-α in tumor prolifer-
ation, through endothelial cell migration, invasion and tube
formation (Wu and Zhou 2010). We previously found a
promigratory effect of the inflammatory cytokine in wound
healing assays performed in cultures of the human endo-
thelial EA.hy926 cell line.Wealso demonstrated endothelial
cellmotility induced by Epo (200 ng/ml) which increased by
coincubation with TNF-α (Maltaneri et al. 2018). With the
aim of characterizing the effect of both cytokines on cell
migration, in the present work, wound healing and other
assays were performed using a substimulatory concentra-
tion of Epo (80 ng/ml). Although no effect of Epo alone was
detected at this concentration, the migration of endothelial
EA.hy926 cells was significantly enhanced by the simulta-
neous presence of Epo and TNF-α (Figure 1).
In a similar experiment, we compared the behavior of
Epo molecules structurally modified by carbamylation
(cEpo) or N-homocysteinylation (HTLEpo) with that of the
native Epo at the same concentration (200 ng/ml). In stark
contrast with Epo, the carbamylated derivative cEpo was
unable to induce cell migration when administered alone,
and coincubation with TNF-α failed to enhance its activity
either at 80 ng/ml (data not shown) or a higher concen-
tration (Figure 1). In a similar way, HTLEpo did not exhibit
significant activity on cell migration when added to the
cultures alone or with the proinflammatory cytokine.
Taken together, the results presented in Figure 1 show that
structural changes – due to protein carbamylation or N-
homocysteinylation – affect the promigratory action of Epo
and its synergistic effect with TNF-α on EA.hy926 endo-
thelial cells.
Effect of TNF-α and erythropoietin on cell
adhesion
The vascular inflammatory reaction is mediated by com-
plex interactions between the circulating leukocytes and
the vascular wall. Endothelial cells regulate the inflam-
matory process by means of the expression of adhesion
molecules, cytokines, chemokines and growth factors.
Various cell adhesion molecules have been identified in
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endothelial cells, such as the intercellular adhesion
molecule 1 (ICAM-1) and the vascular cell adhesion mole-
cule 1 (VCAM-1), which were found upregulated in the
vascular endothelium in response to inflammatory stimuli
(Kim et al. 2008; Lin et al. 2015). Therefore, we were
interested in studying the regulation of adhesion mole-
cules as well as white blood cell adhesion in cultures of
EA.hy926 cells exposed to both TNF-α and Epo. Using
fluorescencemicroscopy and fluorometric quantitation, we
demonstrated that the initial stimulatory effect of TNF-α on
the adhesion ofmonocytic THP-1 cells to EA.hy926 cultures
was significantly increased by the simultaneous presence
of Epo (Figure 2A,B).
The previous result led us to investigate if adhesion
molecules could be involved in this effect and therefore be
upregulated. As expected, mRNA levels of both VCAM-1
and ICAM-1 increased in the presence of TNF-α. However,
this effect was even higher in cells coincubated with TNF-α
and Epo. This demonstrated that when cells were exposed
to both cytokines, expression of adhesion molecules
was enhanced in parallel with monocyte attachment to
activated endothelial cells (Figure 2C,D). It is worth
Figure 1: Synergistic effect of TNF-α and Epo
on endothelial cell migration. Wound
healing assay: After 18 h of serum
starvation (t = 0), EA.hy926 cells were
incubatedwith Epo (80or 200ng/ml), cEpo
(200 ng/ml) or HTLEpo (200 ng/ml) in the
presence or absence of TNF-α (30 ng/ml),
followed by wound healing assay. Cell
migration was assessed by measuring
wound width in photographs taken at
t = 0 h and t = 18 h. Controls consisted of
cells cultured without FBS, and with 10%
FBS (promigratory control). (A)
Photographs are representative of seven
independent assays (Bar: 500 μm). (B) Bars
represent Mean ± SEM. Significant
differences: ∗P < 0.05; ∗∗P < 0.01;
∗∗∗P < 0.001; n = 7. No significant
differences were found between cEpo
200 ng/ml + TNF-α or HTLEpo 200 ng/
ml + TNF-α versus TNF-α.
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mentioning that Epo was used at a concentration which
was insufficient to stimulate cell migration and which was
also unable to induce VCAM-1 and ICAM-1 expression and
monocyte adhesion (Figure 2).
Regarding the modified erythropoietins, neither cEpo
nor HTLEpo had an effect on cell adhesion or on the
expression of the adhesion molecules. The fact that the
modified erythropoietins did not exhibit the promigratory
effect of the native protein (Figure 1B) or its ability to pro-
duce a synergistic effect with TNF-α on the endothelial cell
adhesion process (Figure 2) strongly suggests that these
alterations in the functionality of Epo can be ascribed to
changes in protein structure that lead to the inhibition of
the activation of its receptor.
Figure 2: Coincubationwith TNF-α and Epo stimulatesmonocyte adhesion to endothelial cells. EA.hy926 cells were incubated (18 h) with Epo (80
or 200ng/ml), cEpo (200ng/ml) or HTLEpo (200ng/ml) in thepresence or absenceof TNF-α (30ng/ml), followedby incubation (1h)withmonocytic
THP-1 cells for adhesion analysis. (A) Photographs obtainedby fluorescencemicroscopy show adhesion of CFSE-labelled THP-1 cells to TNF-α- and
Epo + TNF-α-activated endothelial EA.hy926 cells (Bar: 500 μm). (B) Fluorometric quantitation. Bars represent Mean ± SEM of fluorescence
intensity indicated in arbitrary units. Significant differences: ∗P < 0.05; ∗∗P < 0.01,n=7.No significant differenceswere foundbetween cEpo+ TNF-α
or HTLEpo + TNF-α versus TNF-α. (C, D) Detection of VCAM-1 and ICAM-1 mRNA levels by reverse transcription-PCR followed by agarose gel
electrophoresis and real-time PCR. Bars representMean± SEMof VCAM-1 or ICAM-1 expression atmRNA levels relative to the control geneGAPDH
(2−ΔΔCt). Significant differences: ∗P < 0.05; ∗∗P < 0.01; n = 3, (NS) indicates no significant differences with respect to TNF-α.
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Study of the erythropoietin receptor
To investigate the contribution of Epo to the enhanced
migratory ability of endothelial cells when simultaneously
exposed to Epo and TNF-α, we studied the possible acti-
vation of the Epo receptor.
Silencing of EpoR in EA.hy926 cells with a specific
siRNA caused inhibition of the promigratory effect induced
by TNF-α + Epo (80 ng/ml) in wound healing assays.
Similar results were obtained by blocking the receptor with
an anti-EpoR antibody (Figure 3), indicating that the
presence of the inflammatory cytokine sensitized endo-
thelial cells to a promigratory effect of Epo through the
activation of its specific receptor EpoR.
Generation of an oxidative environment
Among the possible mechanisms underlying cell motility,
the rapid generation of small concentrations of ROS has
been associated with the migratory response of cells
stimulated with cytokines such as the vascular endothelial
growth factor (VEGF) (Wang et al. 2011). Therefore, we
investigated the involvement of oxidative species in the
promigratory effect of TNF-α+Epo. The fact that the anti-
oxidant N-acetylcysteine (NAC) prevented EA.hy926 cell
migration in wound healing assays stimulated by TNF-α or
TNF-α + Epo provides evidence of the participation of ROS
in this process (Figure 4A). Moreover, quantification of ROS
levels demonstrated that these species were induced by the
presence of TNF-α, and that they were also significantly
increased in cultures stimulated with TNF-α + Epo, an ef-
fect which was prevented by preincubation with the anti-
oxidants NAC or ascorbic acid (Figure 4B).
GiventhatEpoalonefailedtoproduceROS,weinvestigated
a possible modulation of TNF-α receptors in order to find an
explanation for the increase in oxidant species observed in the
presence of TNF-α+Epo compared to TNF-α alone (Figure 4B).
We found that tumor necrosis factor receptor 1 (TNFR1)
and tumor necrosis factor receptor 2 (TNFR2) were induced
by simultaneous administration of TNF-α and Epo, even
though TNFR2 expression was induced in the presence of
either TNF-α or Epo alone (Figure 4C). The positive modu-
lation of TNF-α receptors in cells exposed toTNF-α+Epomay
explain the increased levels of ROS detected after such
treatment (Figure 4B), and suggests a bidirectional modu-
lation between both cytokines.
Expression and activity of the protein PTP1B
The increased activity of Epo observed in the presence of
TNF-α led us to consider a possible signaling deregulation
affecting the activation status of its receptor. Protein
phosphorylation and dephosphorylation regulate many
aspects of the transduction pathways triggered by Epo
upon binding to EpoR. Taking into account that protein
phosphatases are sensitive to inhibition after generation of
ROS, we were interested in investigating whether the pro-
duction of TNF-α-induced ROS could be responsible for
PTP1B inactivation, thus making the activity of Epo on
endothelial cells more sustained over time.
Experiments on EA.hy926 cell cultures showed that the
combination of TNF-α and Epo decreased phosphatase
activity and expression of PTP1B when compared with the
effect of Epo alone. The induction of PTP1B by Epo was
abrogated when TNF-α was simultaneously added to the
culture medium (Figure 5A). In assays performed in the
presence of both cytokines, a strong inhibition of phos-
phatase activity was detected in PTP1B immunoprecipi-
tates by colorimetric measurement (Figure 5B).
It can be proposed that generation of ROS by the proin-
flammatory cytokine facilitates tyrosine-phosphorylation-
dependent cellular responses by transiently inactivating
PTP1B. When the establishment of an oxidative environment
Figure 3: Involvement of Epo receptor in the synergistic effect of
both cytokines. EA.hy926 cell migration was evaluated by wound
healing assays in the presence of TNF-α with or without Epo. When
indicated, cultures were pre-incubated during 1 h with an anti-EpoR
blocking antibody (400 ng/ml) or transfected with a specific siRNA
against EpoR (siEpoR, 100 nM) 30 h before the experiment. The
conditions used for the inhibition of EpoR, either by siRNA or by a
blocking antibody, effectively impaired the promigratory action of
Epo 200 ng/ml (data not shown). Cell cultures without FBS or with
10% FBS were included as controls. Significant differences:
∗∗P < 0.01, n = 5.
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was not permitted due to preincubation of cell cultures with
antioxidants, such as NAC or ascorbic acid, phosphatase
activity was recovered (Figure 5B). PTP1B inactivation
mediated by TNF-α-induced ROS may increase the period of
cell activation by Epo, thus contributing to explain why Epo
at a low,non-promigratory concentrationbecomes capable of
Figure 4: Cell migration is mediated by ROS
induced by TNF-α. (A) Wound healing assay
with or without NAC (10 mM) in cells treated
with either TNF-α or Epo + TNF-α (80 and 30 ng/
ml, respectively). Significant differences:
∗P < 0.05; ∗∗P < 0.01, n = 5. (B) ROS content was
determined in cells exposed to TNF-α or
Epo + TNF-α by flow cytometry with DCFH-DA.
Cells were pretreated (15 min) with the
antioxidants NAC (10 mM) or ascorbic acid
(5 μM). Each bar represents Geometric
Mean ± SEM of fluorescence. Significant
differences: ∗P < 0.05; ∗∗P < 0.01, n = 8.
Controls: cultures without FBS (Control) and
with 10% FBS. (C) TNFR1 and TNFR2 mRNA
levels in EA.hy926 cells were determined by
reverse transcription-PCR after 18 h exposure
to Epo (80 ng/ml), TNF-α (30 ng/ml) or both in
cell cultures without FBS. PCR products were
resolved through agarose gel electrophoresis
with ethidium bromide staining. Bars
represent Mean ± SEM of band density.
Significant differences: ∗P < 0.05; ∗∗P < 0.01,
n = 5.
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promoting migration when endothelial cells are simulta-
neously exposed to TNF-α.
Signaling pathways involved in the
simultaneous induction of cell migration by
TNF-α and erythropoietin
In order to gain a better understanding of the increased
sensitivity of endothelial cells to the promigratory activity
of Epo in the presence of TNF-α, we went on to investigate
the underlying mechanisms.
The use of specific inhibitors of signaling factors such
as Ly294002 in the wound healing assay showed that the
effect of TNF-α on cell migration is mediated by the acti-
vation of the PI3K pathway. However, in the presence of
both TNF-α and Epo, the use of AG490 and Ly294002
demonstrates the participation of Jak2 and PI3K, factors
involved in the Epo signaling (Figure 6A). In line with
previous results by our group (Maltaneri et al. 2017) this
implies that the promigratory effect of Epo, enhanced by
the presence of TNF-α, is mediated by the classical
signaling pathway triggered after its binding to the
homodimeric receptor (EpoR)2 (Figure 3), consequently
eliciting Jak2 and PI3K activation (Figure 6A).
Chronic inflammation, a condition in which the
proinflammatory cytokine TNF-α induces expression of
endothelial adhesion molecules and recruitment of
monocytes to cytokine-activated endothelium, is associ-
ated with the activation of NF-κB. The expression of
adhesion molecules would be related to the activation of
NF-κB dependent on ROS in endothelial cells (Kim et al.
2008). Taking into account that ROS activate NF-κB, we
investigated if this pathway is also involved in the syner-
gistic promigratory effect of Epo with the proinflammatory
cytokine. Figure 6B shows that the presence of salicylic
acid, an inhibitor of the NF-κB pathway, prevented
EA.hy926 cell migration induced by either TNF-α or TNF-
α + Epo.
A positive feedback loop was suggested between the
mammalian target of rapamycin (mTOR) and NF-κB during
inflammation (Okamoto et al. 2016). In this context, specific
inhibitionofmTORby rapamycinconfirmed the involvement
of this pathway in the increased sensitivity of endothelial
cells to a promigratory action of Epo in an inflammatory
environment generated by TNF-α (Figure 6B). However,
direct activation of NF-κB by TNF-α without involving the
mTOR signaling pathway cannot be ruled out.
Discussion
In the present work, we contributed to identify the mech-
anisms through which endothelial cells are sensitized to
Epo in the presence of TNF-α. Epo, a growth factor that
promotes survival, proliferation and differentiation of
erythroid progenitor cells, has long had therapeutical ap-
plications. Despite the benefits of Epo treatment to over-
come the anemia associated to different pathologies, a
significant number of patients, particularly those with
cardiovascular or chronic renal diseases, fail to respond.
This effect may be explained by the presence of inflam-
mation, a common feature among the multiple
Figure 5: PTP1B inactivation by ROS. (A) Endothelial EA.hy926 cells
treatedwith Epo, TNF-αor bothwere sequentially exposed to an anti-
PTP1B primary antibody and to a secondary antibody bound to Alexa
Fluor 488, to analyze PTP1B expression by flow cytometry. Each bar
represents Geometric Mean ± SEM of fluorescence. Significant
differences: ∗P < 0.05, n = 5. (B) PTP1B phosphatase activity:
EA.hy926 cells were incubated with TNF-α, Epo or Epo + TNF-α for
18 h. When pretreated with NAC (10 mM) or ascorbic acid (5 µM),
antioxidants were added 15 min before the rest of the treatments.
Cell lysates were immunoprecipitated with anti-PTP1B antibody and
phosphatase activity was determined in the pellets by measuring
absorbance at 520 nm after reaction with 4-aminoantipyrine and
potassium ferrocyanide. The activity was expressed as fold increase
with respect to control. Significant differences: ∗P < 0.05; ∗∗P < 0.01,
∗∗∗P < 0.001, n = 5.
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mechanisms associated with chronic anemia. It is known
that proinflammatory cytokines contribute to the short-
ening of red blood cell life span, as well as to the inhibition
of Epo activity on erythroid cells (Weiss et al. 2019). In other
cell types, some stimuli may exert different effects when an
inflammatory environment is established. As it has previ-
ously been reported, TNF-α is able to induce endothelial
cell migration and angiogenesis (Sainson et al. 2008; Shu
et al. 2012). Previous research has shown that TNF-α also
induces the expression of adhesion molecules, such as
VCAM-1 and ICAM-1 (Kim et al. 2008; Lin et al. 2015; Shirai
et al. 2018), and stimulates adhesion of the promonocytic
U-937 cell line to an endothelial monolayer (Stangl et al.
2001; Yamagata et al. 2015).
When stimulated, endothelial cells exhibit a shift from
a quiescent to a proangiogenic phenotype. Given that the
processes of cell proliferation and migration respond to
inflammation, it can be suggested that proinflammatory
cytokines may enhance the effects of promigratory factors.
In this context, our present findings demonstrate that Epo,
at a concentration which does not normally promote cell
migration, acquires the ability to induce the motility of
endothelial cells in the presence of TNF-α (Figure 1). This
synergistic effect between TNF-α andEpo onEA.hy926 cells
was also observed in the upregulation of VCAM-1 and
ICAM-1, which subsequently leads to the adhesion of THP-1
monocytes to endothelial cells (Figure 2), a mechanism
that in vivo facilitates migration of immune cells to the
subendothelial space. Previous studies have shown that
Epo enhances endothelial cellmigration (Anagnostou et al.
1990; Du et al. 2013; Maltaneri et al. 2017). Taking into
account that in our work Epo was used at a concentration
which was insufficient to stimulate cell migration
(Figure 1), monocyte adhesion or VCAM-1 and ICAM-1
expression (Figure 2), we hypothesized that EA.hy926
endothelial cells are sensitized to a promigratory effect of
Epo in the inflammatory environment generated by TNF-α.
To explain the synergistic effect of TNF-α and Epo, we
first investigated the expression of cellular receptors that
mediate the effect of these cytokines on endothelial cells.
EpoR activation upon Epo binding was demonstrated by
the decrease in cell migration in cultures stimulated with
TNF-α + Epo when EpoR was blocked by an anti-EpoR
antibody or its expression was knocked down by a siRNA
against EpoR (Figure 3). With respect to TNF-α receptors,
we observed that both TNFR1 and TNFR2 mRNA levels
significantly increased with Epo + TNF-α (Figure 4C),
whereas TNFR2 was also augmented in the presence of
each of the cytokines separately. Recent evidence suggests
that a TNF-α-mediated signaling pathway via TNFR1 leads
to a proinflammatory state, while TNF-α binding to TNFR2
mainly triggers immune modulation and tissue regenera-
tion (Yang et al. 2018). However, other authors reported
that TNF-α promoted cell proliferation and survival in a
mouse prostate cancer model through its receptor TNFR1,
which induced the activation of the AKT/mTOR and NF-κB
pathways (Galheigo et al. 2016). In line with our results,
Taoufik et al. (2008) reported that induction of EpoR
expression in primary cortical neurons after glucose
deprivation largely depended on TNFR1 and was upregu-
lated by TNF-α. In this case, the cell sensitizing effect of
TNF-α enhanced the neuroprotective ability of Epo.
Figure 6: Epo and TNF-α share the same intracellular signaling
pathways. The signaling pathways involved in the synergistic effect
of Epo + TNF-α were evaluated by cell migration in the presence or
absence of inhibitors. (A) Jak2 inhibitor (AG490, 25 μM); PI3K
inhibitor (Ly294002, 25 μM). Significant differences: ∗∗P < 0.01,
∗∗∗P < 0.001, n = 5. (B) IkB phosphorylation inhibitor (salicylic acid,
10 μM); mTOR inhibitor (rapamycin, 100 nM). Bars represent Mean ±
SEM. Significant differences: ∗P < 0.05; ∗∗P < 0.01, n = 4.
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More information related to the signaling pathway
involved in the cooperative action of Epo and TNF-α on
endothelial cell arose through results of wound healing as-
says in the presence of inhibitors (Figure 6). Upon binding of
their respective ligands, EpoR and TNFR2 may activate the
same signaling pathway involving PI3K, and leading to cell
proliferation among other effects, as previously reported
(Pegoretti et al. 2018; Zhao et al. 2017). This can explain, at
least in part, the enhanced migration observed in endothe-
lial cells coincubated with TNF-α + Epo.
The fact that the antioxidants NAC and ascorbic acid
prevented cell migration stimulated by either TNF-α or TNF-
α + Epo inwound healing assays confirmed the involvement
of ROS in this process (Figure 4A). These findings were
consistent with the levels of intracellular ROS measured by
flow cytometry with the DCFH-DA probe, which increased
due to treatment with either TNF-α or TNF-α + Epo and were
counteracted in the presence of the antioxidants NAC and
ascorbic acid (Figure 4B). In this context, it is important to
consider that stimulation of vascular endothelial cells by
inflammatory cytokines causes the activation of NADPH
oxidase, which plays a key role in the generation of ROS
(Frey et al. 2009) that activate a variety of redox signaling
pathways linked to angiogenesis (Ushio-Fukai 2006).
The finding of ROS involvement in the observed syn-
ergistic effect of Epo and TNF-α (Figure 4) on endothelial
EA.hy926 cells may be ascribed to the modulation of ki-
nases that converge to the activation of theNF-κB signaling
pathway. NF-κB, which is among the most important
transcription factors that are activated by oxidative stress
(Haddad and Abdel-Karim 2011), is also a downstream
element of the PI3K/AKT/mTOR pathway (Lee et al. 2012).
The regulatory protein mTOR, involved in the promotion of
cell growth, response to nutrients and cell death suppres-
sion, is induced in inflammatory conditions, as suggested
by experiments in animal models of atherosclerosis (Liu
et al. 2011) and skin disease (Buerger et al. 2017). In the
present work, Epo and TNF-α were unable to induce cell
migration in the presence of inhibitors of the mTOR/NF-κB
pathway, such as rapamycin and salicylate, respectively
(Figure 6). Taken together, the results hint at a common
activation pathway for both cytokines, thus supporting the
synergistic effect between them.
In order to explain the promigratory effect of Epo
observed in an inflammatory environment, the finding of
ROS generation and overexpression of adhesion molecules
as markers of an inflammatory process prompted us to
investigate whether oxidative species may affect signaling
pathways involved in cell activation via EpoR. Upon acti-
vation, negative EpoR regulators downmodulate the cellular
response to Epo. Internalization of the receptor,
ubiquitination and subsequent degradation by the protea-
some is one of the mechanisms involved (Walrafen et al.
2005). Since the phosphorylation of protein tyrosyl residues
by protein tyrosine kinases is a critical event in many
signaling pathways related to proliferation, differentiation
andother biological activities of Epo, PTPbecome important
factors in the downregulation of such activities. Oxidative
stress is closely related to PTP regulation, as demonstrated
by findings of phosphatase activation or inactivation
through ROS. Among these enzymes, PTP1B has been
characterized as a negative regulator of cell activation by
Epo/EpoR signaling (Callero et al. 2007, 2011; Cohen et al.
2004). PTP1B oxidationmediated by ROSwas demonstrated
in in vitro and in vivo assays (Bogeski et al. 2006; Lee et al.
1998; Mahadev et al. 2001; Meng et al. 2002; vanMontfort et
al. 2003) and it has been reported that oxidation of the
catalytic Cys residue causes structural modification and
inactivation of PTP1B (van Montfort et al., 2003). Based on
the hypothesis that signaling downmodulation is involved
in the increasedpromigratory effect of Epo in thepresence of
TNF-α, we investigated if PTP1B expression and/or activity
could be modified in an inflammatory environment. As ex-
pected, in flow cytometry assays we found induction of
PTP1B expression by Epo (Figure 5A), as well as an increase
in the PTP1B activity measured in cell immunoprecipitates
using anti-PTP1B antibody (Figure 5B). However, these ef-
fects were fully abrogated by the simultaneous treatment
with Epo and TNF-α. The increased enzymatic activity
measured in EA.hy926 cell cultures preincubated with the
antioxidants NAC or ascorbic acid and then exposed to TNF-
α + Epo confirms the hypothesis that ROS decreases PTP1B
activation (Figure 5B). These results are in accordance with
data reported by Mußbach et al. (2015), showing that inhi-
bition of ROS by NAC prevented the abrogation of PTP1B
induced by PAR1-AP and the PAR4-AP in Hep3B cells. This
way, the reversible oxidation of the enzyme in an inflam-
matory context may explain PTP1B inactivity.
In previous works of our group, we demonstrated
that structural alterations in the Epo molecule, either by
carbamylation (cEpo) or by N-homocysteinylation
(HTLEpo), did not allow the modified proteins to behave
in the same way as the native one. While cEpo maintains
the antiapoptotic ability of Epo in neuronal cell cultures,
it fails to act as an erythropoietic growth factor or as a
stimulus for endothelial cell migration (Chamorro et al.
2013, 2015; Maltaneri et al. 2017). On the other hand, the
reaction of lysine residues in the Epo molecule with ho-
mocysteine thiolactone induces protein aggregation that
prevents an adequate Epo/EpoR interaction (Schiappa-
casse et al. 2018). In the present work, the modified
erythropoietins did not exhibit promigratory action even
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at high concentration (200 ng/ml), and failed to produce
a synergistic effect with TNF-α (Figure 1). The inability of
cEpo and HTLEpo to exert the same biological effects of
the native Epo was also reflected in assays where such
derivatives failed to induce the expression of adhesion
molecules in EA.hy926 cells as well as the adhesion of
THP-1 cells to the endothelial monolayers (Figure 2).
Therefore, these results should be taken into consider-
ation in the treatment of renal and cardiovascular pa-
tients undergoing Epo therapy who may concurrently
show hyperhomocysteinemia or high levels of urea.
Conclusions
The increased sensitivity of endothelial cells to a promi-
gratory effect of Epo in an inflammatory environment
generated by TNF-αmay be ascribed to a cascade of events.
The simultaneous treatment of TNF-α with a low, non-
promigratory concentration of Epo not only stimulated cell
migration, but also the expression of adhesion molecules,
thus increasingmonocyte adhesion. The results demonstrate
the involvement of the classical signalingof cell activationby
Epo and the participation of the NF-κB and mTOR pathways
in the effect of Epo and TNF-α on the endothelial EA.hy926
cell line (Figure 7). Moreover, not only EpoR but also TNFR1
and TNFR2 are involved in the increased cell migration
induced in the presence of TNF-α + Epo. The finding of
signaling pathways shared by Epo and TNF-α, as well as the
generation of reactive oxygen species by TNF-α provides an
explanation for the synergistic action of both cytokines. As
ROS inhibit PTP1B, lower levels of PTP1B activity allow Epo/
EpoR signaling to last longer and therefore the cell remains
activated by Epo for an extended period, thus causing the
activation of common signals. These results demonstrate
that the proangiogenic ability of Epo may be enhanced in a
proinflammatory environment where TNF-α is released. This
may favor the action of Epo as a vascular protectant in
ischemia and as a mediator of leukocyte migration depen-
dent on adhesion molecules. However, such effects may be
carefully considered in some pathophysiological entities in
which tumor angiogenesis or excessive leukocyte adhesion
becomes a risk factor.
Materials and methods
Materials and reagents
All the chemicals used were of analytical grade. Iscove’s modified
Dulbecco’s medium (IMDM), RPMI-1640 medium, penicillin–
streptomycin and TrypLE were obtained from Gibco-Thermo Fisher
Scientific (Waltham, MA, USA). Fetal bovine serum (FBS) was from
Natocor (Córdoba, Argentina). TNF-α, Cytofix/Cytoperm and Perm
Wash buffer were from BD Biosciences (San José, CA, USA). NAC,
rapamycin, HTL and DCFH-DA were obtained from Sigma-Aldrich (St.
Louis, MO, USA). Ascorbic acid was from Carlo ERBA (Sabadell,
Spain). The antibodies against EpoR (M-20, sc-697) and PTP1B (H-135,
sc-14021), as well as the siRNA targeting EpoR (sc-37092) and the
siRNA against green fluorescent protein (GFP) (sc-45924) were from
Santa Cruz Biotechnology (CA, USA). The inhibitors Ly294002 and
AG490 were obtained from Calbiochem/Millipore (County Cork,
Ireland). The reverse transcription kit containing Moloney Murine
Leukemia Virus (M-MLV) reverse transcriptase, Ribonuclease inhibi-
tor and oligodTs was from Promega (Madison, WI, USA). Specific
primers for ICAM-1, VCAM-1, TNFR1, TNFR2 and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), the TRIzol reagent, the fluores-
cent probe carboxyfluorescein succinimidyl ester (CFSE), the trans-
fection reagent Lipofectamine 3000, the transfection culture medium
OptiMEM and the secondary antibody conjugated with Alexa Fluor
488 were from Invitrogen Life Technologies (Waltham, MA, USA).
Phosphatase activity was measured with an alkaline phosphatase kit
from Wiener lab (Warsaw, Poland). Recombinant human erythropoi-
etin was kindly supplied by Zelltek (specific activity: 125 IU/μg;
Mr = 30,243 as determined by MALDITOF MS) (Santa Fe, Argentina).
Carbamylation and N-homocysteinylation of
erythropoietin
The structural transformation of Epoby carbamylationwith potassium
cyanate was performed as described by Leist et al. (2004) with modi-
fications made in our laboratory (Chamorro et al. 2013). For N-homo-
cysteinylation, Epo was incubated in the presence of HTL at an Epo:
HTLmolar ratio of 1:500 in phosphate buffered saline (PBS) for 24 h at
37 °C. Purification was performed as described before (Schiappacasse
et al. 2018).
Analysis by capillary zone electrophoresis (Beckman Coulter,
Carlsbad, CA, USA) revealed structural changes in comparison to the
native protein. Since carbamylation and N-homocysteinylation —due
to reaction with potassium cyanate or HTL, respectively – caused the
Figure 7: Schematic illustration of the proposed mechanisms
involved in the simultaneous induction of cell migration by TNF-α
and Epo.
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transformation of the lysine residues of Epo, cEpo and HTLEpo dis-
played an increased electrophoretic mobility compared to Epo, which
is explained by the expected loss of positive net charge of themolecule
(data not shown).
Cell cultures
The endothelial cell line EA.hy926, derived from the fusion of human
umbilical vein endothelial cells (HUVEC) and the adenocarcinoma cell
line A549 (Edgell et al. 1983), was kindly supplied by Dr. Fernanda
Parborell (IBYME-CONICET, BuenosAires, Argentina)with permission
from Dr. Gareth Owen (Pontificia Universidad Católica, Chile). Cul-
tures were maintained on IMDM supplemented with 10% heat-inac-
tivated FBS (v/v), 100 U/ml penicillin and 100 μg/ml streptomycin.
Cells were subcultured upon reaching 80–90% confluence and were
used up to passage 18, due to cell senescence. In order to replicate the
physiological quiescent state of the endothelium, cells were deprived
of FBS before treatment, and experiments were carried out in FBS-free
medium.
The human monocitic cell line THP-1 (ATCC TIB-202), derived
from an acute monocytic leukemia, was cultured in RPMI 1640 me-
dium supplemented with 10% heat-inactivated FBS (v/v), penicillin
100 U/ml, streptomycin 100 μg/ml, 1% glutamine, 250mg/ml glucose,
11 mg/l sodium pyruvate and 50 μM β-mercaptoethanol. Cultures were
maintained at a density of 1.5x105 cells/ml.When treated with phorbol
12-myristate 13-acetate (PMA), THP-1 cells acquire the morphological
and functional features of macrophages, such as adherence to crystal
surfaces.
All cell cultures were maintained at 37 °C and 5% CO2, with
replacement of culture media every three days.
Cell migration (wound healing) assay
Cells were seeded on 24-well plates (80,000 viable cells/well) and
allowed to attach overnight on growth medium. After washing with
PBS, cellswere FBS-deprived for 18 h before practicing a scratchwith a
pipette tip and adding the corresponding treatments. FBS (10%) was
added as a cell migration control. Images were obtained at the
beginning (t = 0) and at the end of the experiment (t = 18 h) using an
inverted microscope Axiovert 135 (Carl Zeiss, Birkerød, Denmark) and
a Nikon Coolpix 5000 camera, and digitalized with the Axiovision
software (Birkerød, Denmark). For each independent experiment, cell
migration was quantified by averaging four different fields per treat-
ment. Inhibitors were added at least 15 min before the assays.
A 18 h incubation was chosen so that the contribution of cell
proliferation to wound closure would be insignificant, according to
our previous studies on EA.hy926 cell growth (Maltaneri et al. 2017).
Cell adhesion
THP-1 cultures (approximately 105 cells) were labeled with CFSE
(0.5 μM in PBS) for 15 min at 37 °C. Subsequently, cells were washed
twice with RPMImedium and resuspended in 100 µl of medium before
being added to EA.hy926 cultures for 1 h. Then, to remove non-
adherent cells, each well was carefully washed by addition of pre-
warmed RPMI, followed by gentle swirling and inversion of the plate
and blotting of excess liquid onto absorbent paper. This was repeated
three times, and 100 µl of PBS were added to each well. The images
were taken with the fluorescent microscope Axiovert 135 (Carl Zeiss)
coupled with a Nikon Coolpix 5000 camera. Relative fluorescence was
measured using an Optima FluorSTAR fluorometer (BMG Labtech,
Offenburg Germany) set at 485 nm excitation wavelength and 530 nm
emission wavelength.
RNA isolation, reverse transcription and real time-PCR
RNA extraction was performed using the TRIzol reagent, according
to manufacturer’s protocol. Nucleic acid quantification was per-
formed using NanoDrop equipment (Thermo Scientific, MA, USA).
RNA samples with a 260/280 nm ratio above 1.80 and a 230/260 nm
ratio close to 0.5 were considered pure from protein and organic
contaminants, respectively. Reverse transcription of 1 μg total RNA
was M-MLV reverse transcriptase. PCR master mixes were prepared
with 1.5 mM MgCl2, 0.2 mM dNTPs and the corresponding primers at
0.25 mM (final concentrations). The sequences of the primers used
were as follows: VCAM-1, forward: 5′- TTGGGAACGAACACTCTT-
ACCTG-3′, reverse: 5′-AGTCTATCTCCAGCCTGTCAAATG-3′ (195 bp);
ICAM-1, forward: 5′-CGTGCCGCACTGAACTGGAC-3′, reverse: 5′-
CCTCACACTTCACTGTCACCT-3′ (447 bp); TNFR1, forward: 5′-TCG-
ATTTGCTGTACCAAGTG-3′, reverse: 5′- GAAAATGACCAGGGGCAA-
CAG-3′ (492 bp); TNFR2, forward: 5′-CCAGTGCGTTGGACAGAA-3′,
reverse: 5′-GGCTTCATCCCAGCATCA-3′ (376 bp) and GAPDH, for-
ward: 5′-TGATGACATCAAGAAGGTGGTGAAG-3′, reverse: 5′-TCC-
TTGGAGGCCATGTAGGCCAT-3′ (240 bp). Amplification of VCAM-1
consisted of 40 cycles of denaturation at 95 °C for 10 s, annealing at
56 °C for 30 s and extension at 72 °C for 20 s; ICAM-1 consisted of 40
cycles of denaturation at 95 °C for 15 s, annealing at 60 °C for 15 s and
extension at 72 °C for 25 s. The program used for TNFR1 consisted of
35 cycles of denaturation at 94 °C for 1 min, annealing at 53 °C for
2 min and extension at 72 °C for 2 min, and TNFR2 consisted of 35
cycles of denaturation at 94 °C for 1 min, annealing at 56 °C for 1 min
and extension at 72 °C for 1 min. PCR products were resolved on 2%
agarose gels stained with 0.05% ethidium bromide. Fluorescence of
DNA was detected with a G:BOX Chemi system and digitalized using
the GeneSys software (Syngene, Cambridge, UK). Relative quantifi-
cation of mRNA levels was performed through band densitometry
with the ImageJ software, using GAPDH as a housekeeping gene.
Real time PCRwas carried out in a My IQ2 thermocycler (Bio-Rad,
Hercules, CA, USA), and results were analyzed using the CFX software
(Bio-Rad). The relative gene expression levels were determined using
the threshold cycle (CT) method (2−ΔΔCT method) normalized to the
endogenous control gene GAPDH.
ROS levels by flow cytometry
At the endof treatments, EA.hy926 cellswerewashedwith PBSat room
temperature and incubated (30 min, 37 °C) with DCFH-DA (20 μM in
PBS). Cells were then collected with TrypLE, centrifuged and fixed in
0.5% paraformaldehyde/PBS. Event acquisition was performed in a
flow cytometer (FACS Aria II, BD, San José, CA, USA). Data were
analyzed using the FlowJo software (FlowJo LLC, Turku, Finland).
PTP1B expression by flow cytometry
After experimental treatments, EA.hy926 cells were collected by
centrifugation and washed with 2% FBS in PBS. Cells were then
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incubated with Cytofix-Cytoperm for 20 min and centrifuged (350 g,
10 min) before adding an anti-PTP1B antibody (30 min, 4 °C). Samples
werewashedwith PermWashbuffer and then incubatedwith anAlexa
Fluor 488-bound secondary antibody (30 min, 4 °C). Events were ac-
quired in a FACS Aria II flow cytometer (BD, San José, CA, USA) and
data were analyzed using the FlowJo software (FlowJo LLC).
Phosphatase activity
Protein immunoprecipitation:Cellswerewashedwith ice-cold PBSand
lyzed in a hypotonic buffer (50mMTris pH 8.0, 150mMNaCl, 1% Triton
X-100) containing protease inhibitors (1mMPMSF, 4 μM leupeptin, 2 μM
pepstatin), in a ratio of 200μl/107 cells. After 30minof incubationon ice,
samples were centrifuged (15,000 g, 15 min) to remove insoluble ma-
terial. Cell lysate aliquots equivalent to 1 mg total protein were immu-
noprecipitated with anti-PTP1B antibody at 2 μg/ml final concentration
(4 °C for 1 h with gentle agitation). Protein A-agarose was added and,
after overnight incubationwith rotation at 4 °C, immunocomplexeswere
collected by centrifugation at 15,000 g for 15 min.
PTP1B activity: The activity of PTP1B in the immunoprecipitates was
determined by incubation at 37 °C for 10 min using an alkaline phos-
phatase kit in which the enzyme breaks the sodium phenylphosphate.
The freed phenol reacts with 4-aminoantipyrine and potassium ferri-
cyanide yielding a colored product. The color intensity, which is
proportional to the enzymatic activity, was measured at 520 nm in a
microplate reader (Bio-Rad, Hercules, CA, USA).
Silencing of EpoR with siRNA
Pre-manufactured siRNA duplexes targeting EpoRwere delivered into
EA.hy926 cells with Lipofectamine 3000, according to manufacturer’s
instructions. Preliminary assays carried out in EA.hy926 cultures
allowed us to determine an optimal final concentration of 100 nM for
EpoR silencing. We observed a decrease in mRNA levels (RT-PCR) as
early as 24 h post-transfection, although EpoR protein expression was
at its lowest after 48 h (data not shown). Based on these optimization
assays, cultures were transfected with the siRNA before the onset of
the wound-healing experiments, so that the 18 h incubation would
coincidewith the period of EpoRdownregulation. The conditions used
correspond to 88% of the EpoR silencing (data not shown). As a
transfection and knock-down control, a pre-manufactured siRNA
against the green fluorescent protein (GFP) was used at the same final
concentration (data not shown).
To deliver the siRNAs into the cells, cultures were incubated in
OptiMEM medium 1 h before the addition of Lipofectamine
3000 + siRNA complexes for 6 h, at the end of which the medium was
replaced with 10% FBS-supplemented IMDM without antibiotics.
Statistics
The Graph Pad Prism software (GraphPad Software Inc.) was used for
statistical analysis. Results are expressed as mean ± standard error of
the mean (Mean ± SEM) of three or more independent experimental
replicates. Kruskal–Wallis one-way analysis of variance was followed
by Dunn’s test for comparison among groups. Least significant dif-
ference with P < 0.05 was the criterion for statistical significance.
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